Regeneron stock falls on test data
-
- May
- 21
Disappointing data in a clinical trial of a treatment for ovarian cancer sent stock in Regeneron Pharmaceuticals Inc. of Eastview tumbling today.
The company and its research partner, Sanofti-aventis of Paris, said that a phase 2 study of 215 women with advanced ovarian cancer showed no significant response to a drug called aflibercept. The compound is a fused protein that aims to inhibit the growth of tumors by starving them of blood.
Regeneron stock was down as much as 16 percent. It closed yesterday at $18.58, down $2.89 or 13.5 percent. It was down 23.1 percent for the year.
In a statement, the company said there are few treatment options for advanced ovarian cancer.
“We and Sanofi-aventis are continuing to evaluate the data from this trial in order to determine the next steps for aflibercept in advanced ovarian cancer,†Dr. George Yancopoulos, Regeneron’s president, said in the statement.
Sanofi is Regeneron’s largest shareholder, with 19 percent of its stock.
Joseph Pantginis, an analyst who follows the company for Canaccord Adams, said part of the selloff in the stock may have been related to the larger drop in the markets yesterday. The announcement contained some good news about other drug trial results, he said, and Regeneron and Sanofi are testing aflibercept in four phase 3 trials that combine the drug with chemotherapy.
“Overall, the profile of the drug still looks very promising for other indications,†said Pantginis, a former scientist at Regeneron. He said he holds no shares of company stock.
This entry was posted
on Wednesday, May 21st, 2008 at 3:43 pm by Jerry Gleeson.
You can follow any responses to this entry through the RSS 2.0 feed.
Print
| 
Email
